Conclusion:
In this real-world study, we offer additional consideration of vancomycin dosing in obese and extremely obese patients. Extremely obese patients may require a lower weightbased daily dose than obese patients to reach target vancomycin trough concentrations.
According to the Centers for Disease Control and Prevention, the prevalence of obesity has increased over the past 20 years. 1 More than one third of adults were obese in the United
States in 2011-2012, which corresponds to over 78 million adults. 1 This is concerning since obesity is associated with an increased risk of infection as well as increased morbidity and mortality. [2] [3] [4] For years, vancomycin, a glycopeptide antibiotic, has served as the standard of care for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
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Vancomycin exhibits a time-dependent antibacterial effect, and the area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) ratio is the best predictor of clinical efficacy. 8 Several studies suggest a target AUC/MIC ratio of ≥ 400 to achieve clinical effectiveness. 9, 10 A vancomycin consensus review recommends maintaining serum trough concentrations between 15-20 mg/L for complicated infections, such as pneumonia, to achieve target AUC/MIC ratios when the vancomycin MIC is ≤ 1 mg/L. 8 Empiric vancomycin doses of 15-20 mg/kg of actual body weight (ABW) given every 8-12 hours are recommended for most patients with normal renal function to achieve these target serum concentrations. 8 Additionally, a loading dose of 25-30 mg/kg should be considered in seriously ill patients to achieve target concentrations quickly. 8 MRSA guidelines provide similar recommendations for vancomycin dosing and monitoring. 11 Unfortunately, data are limited on the optimal dosing of vancomycin in obese patients.
Moreover, it is presently unknown whether dosing recommendations should change based on different weight categories among obese patients. Despite this, the vancomycin consensus review recommends that initial doses for obese patients should be based on ABW and that dosage adjustments be made based on serum trough levels to achieve optimal concentrations. 8, 12 No special recommendations for extremely obese patients are provided. 8 Optimizing vancomycin therapy in obese and extremely obese patients remains a challenge for clinicians. As knowledge of antimicrobial pharmacokinetics is limited, and assessment of distribution and elimination are skewed in extremely obese patients, underdosing or overdosing can easily occur. A better understanding of the role of extreme patient weight on vancomycin dosing is needed. As such, we sought to compare the effects of empiric vancomycin dosing regimens on attainment of optimal target trough concentrations in a realworld cohort of obese and extremely obese patients.
Methods

Data Sources
We We included patients with trough concentrations measured at steady state (i.e., after at least three vancomycin doses) and measured < 2 hours before the next vancomycin dose ( Figure 1 ). 8 Patients were included if they had no evidence of acute kidney injury (defined as an increase in serum creatinine concentration of 0.5 mg/dL or 50% prior to starting vancomycin). For categorical data, we used a Fisher exact or  2 test to evaluate differences between the obese and extremely obese groups. For continuous data, we used a t test for normally distributed data and the Wilcoxon rank sum test for nonparametric data. We used logistic regression models to measure the effect of initial maintenance weight-based daily vancomycin dosing regimens on target versus subtherapeutic and supratherapeutic trough attainment in obese and extremely obese patients, controlling for renal function. Renal function was estimated by using the Cockcroft-Gault equation using adjusted body weight. All analyses were performed using SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC).
Results
We identified 334 vancomycin-treated patients from our original cohort with trough concentrations ( Figure 1 ): 263 patients (78.7%) in the obese group and 71 patients (21.3%) in the extremely obese group (ABW range 72-244 kg in both groups) ( Table 1 
Discussion
Clinicians face extreme difficulty when properly dosing vancomycin in obese and extremely obese patients. This is exemplified by the wide range of total daily doses observed in our study patients (500-6000 mg/day). Almost half of our patients (48%) had subtherapeutic trough concentrations. Data are consistent with most published reports on vancomycin dosing in obese patients and ability to achieve "target concentrations." [15] [16] [17] In a small study that included 37 obese patients, 57% had trough levels <15 mg/L. 17 In a multicenter study, 99% (252/254 patients) of overweight and obese patients did not receive the recommended vancomycin dose (15 mg/kg/dose). 15 Underdosing vancomycin is a serious concern, as it can lead to inadequate serum vancomycin concentrations and poor penetration at the site of infection, development of resistance, and potentially poor clinical outcomes. 8, 10 In our study, in obese patients, doses <10 mg/kg/day were associated with a lower odds of target trough attainment.
We found that the standard vancomycin dose (~30 mg/kg/day) may be appropriate in obese patients. Previous studies have demonstrated that while obese patients required higher total daily doses than normal-weight patients, no significant differences in weight-based daily doses were required to reach target vancomycin concentrations. 12, 18 In both of these small studies, the standard dose of ~25-30 mg/kg/day was required to achieve target trough concentrations in both normal-weight and obese patients. However, both of these studies included young patients (aged 25-40 years) with good renal function. In our study, over 50% of our cohort were aged 65 years or older. Most patients (68%) had reduced renal function. This may explain why most patients in our study were dosed every 12-24 hours, despite recommendations that vancomycin be dosed more frequently in obese patients (every 8 hours)
due to altered pharmacokinetic parameters, including a shorter half-life and increased clearance.
12, 18
We also found that extremely obese patients may require lower weight-based daily doses (20-25 mg/kg/day) than obese patients. A single-center retrospective study found that a group of patients treated according to a revised protocol (n=74) using lower doses (10 mg/kg every 12 hours or 15 mg/kg every 24 hours) had improved attainment of target trough concentrations compared with a group of patients treated according to an original protocol (n=64) using standard doses (15 mg/kg every 8-12 hours), with 56% attainment in the revised protocol group versus 36% in the original protocol group. 16 As expected, the mean dose administered was lower in the revised protocol group compared to the original protocol group before and after introduction of these guidelines. Among those who did achieve target trough concentration attainment (67 patients), the most frequent dose was the standard dose (2000 mg/day) in both obese and extremely obese patients. This is in contrast to a recent prospective pharmacokinetic study in extremely obese patients, in which dosing simulations indicated that much higher doses (4000-5000 mg/day) were necessary for a high probability of target attainment. 20 However, that study also found that patients with lower renal function may require lower doses. Our results suggest that the standard dose of vancomycin may be appropriate at least initially in obese and extremely obese elderly patients. If the standard dose is used initially, it is important to make dosage adjustments promptly based on therapeutic drug monitoring. Recent evidence suggests obtaining two serum vancomycin concentrations in obese patients to improve target trough attainment. 21 There are several limitations to our findings. We only assessed trough levels associated with initial empiric vancomycin dosing. We did not assess changes in vancomycin dose or trough concentrations later in therapy. Therefore, results may not extend to levels beyond this period. We cannot ensure that troughs remained at the levels we observed later in therapy.
Moreover, as obese patients show an increased volume of distribution and clearance, vancomycin may not have been at steady state. Additionally, we did not assess the impact of loading doses, as the first dose was only higher than subsequent doses in < 5% of our patients, and this dose was often well below the recommended loading dose of 25-30 mg/kg.
As vancomycin has a half-life of 5-8 hours, collection of a level within 2 hours before the next dose may not reflect a true trough level, therefore leading to misclassification of the trough as target, subtherapeutic, or supratherapeutic. Ideally, a trough level should be measured just before the next dose; however, this is not always feasible in clinical practice. 8 This is
exemplified by the fact that by using our "relaxed" criteria of collection of a level within 2 hours (and also relaxed acute kidney injury criteria), only ~10% of our original vancomycin-treated cohort of over 2500 patients met inclusion criteria. However, we did find similar results in a subset of obese patients with a trough level obtained within 30 minutes of the next vancomycin dose.
Due to the retrospective nature of this study, multiple serum vancomycin concentrations and MICs were not available for all patients, thus precluding our ability to calculate AUC/MIC ratios. As the purpose of trough measurement is to serve as a surrogate of AUC, this is a major limitation of our study. Our study, however, reflects real-world clinical practice, where it is often infeasible to calculate AUC/MIC ratios. Many busy clinicians lack the time for collection of multiple levels and/or the training needed for subsequent AUC/MIC calculation.
As the focus of our study was to evaluate empiric vancomycin dosing in obese and extremely obese patients, we did not assess outcomes or toxicity. We assumed that a trough level of 15-20 mg/L was the most optimal target for our obese and extremely obese patients based on vancomycin consensus recommendations. 8 It is largely unknown which trough level is most optimal and associated with the best outcomes in obese and extremely obese patients with MRSA pneumonia. Furthermore, vancomycin does not display simple pharmacokinetics.
Therefore, the ability to reach this narrow window may be limited, and it may not be the best target for clinical success.
Our study is further limited by the relatively small sample size. Finally, the generalizability of our findings to general U.S. population may be limited, as our study was conducted in a VA population, consisting of mostly older men.
Conclusion
We contribute to the literature by offering additional consideration on the dosing of vancomycin Figure 1 . Diagram of the study cohort identification process. *Patients were included if they had an appropriately collected through level. This was defined as a trough that was measured < 2 hours before the next vancomycin dose or within 2 hours of the average interval between the 2 prior vancomycin doses. To avoid not including patients in whom a next dose was never given or was given late, we also defined an appropriate trough as one in which the time from the last dose before the level to the level was < 2 hours different that the average tau (the average interval between the 2 prior vancomycin doses). **Patients who were shorter than 4 ft 3 inches were likely amputees since this is a Veteran population. To increase the generalizability to the general United States population, patients under this minimum height were exlcuded. BMI= body mass index; MRSA= methicillin-resistant Staphylococcus aureus; VAN= vancomycin; SCr= serum creatinine concentration 
